bioAffinity to Present Positive CyPath Lung Data at NAVREF 2026 Conference
bioAffinity Technologies will present data on its CyPath Lung diagnostic system at NAVREF, demonstrating benefits in clinical practice and for veteran populations. The conference highlights the company's efforts to address lung cancer among veterans and commercial potential with new partners.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed